• Mashup Score: 0
    Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19 - 8 month(s) ago

    Patients treated recently for a B-lymphoid malignancy are shown to have particularly high risks of severe COVID-19 compared to multiple control cohorts of patients with cancer and COVID-19.

    Source: aacrjournals.org
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of mtmdphd
      mtmdphd

      Patients recently treated for B-lymphoid malignancies show increased risk of severe COVID-19: a #CCC19 registry analysis [Mar 9, 2022] @rubinstein_md et al. @mtmdphd @COVID19nCCC @BCD_AACR https://t.co/IMEbvgZafi #COVID19nCancer #COVID19 #bmtsm #leusm #lymsm #mmsm #mpnsm https://t.co/5nOgKCsDfP

  • Mashup Score: 1
    Survival in Patients With Hematologic Cancers and COVID-19 - 8 month(s) ago

    This cohort study evaluated the association of convalescent plasma treatment with 30-day mortality in hospitalized adults with hematologic cancers and COVID-19.

    Source: jamanetwork.com
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of mtmdphd
      mtmdphd

      Convalescent Plasma and Survival in Hematologic Malignancy and COVID-19 [Jun 17, 2021] @mtmdphd & @DrJPHenderson et al. @jwsenefeld @DrDimpyShah @hemoncwarner @COVID19nCCC - @JAMAOnc https://t.co/g3GP7EsUeS #COVID19CP #CCC19 #COVID19nCancer #COVID19 #IDonc https://t.co/vrVrF5D0i8

  • Mashup Score: 1
    Real-World Third COVID-19 Vaccine Dosing and Antibody Response in Patients With Hematologic Malignancies - 8 month(s) ago

    Purpose: This study sought to describe the changes in immune response to a third dose of either Pfizer’s or Moderna’s COVID-19 mRNA vaccine (3V) among patients with hematologic malignancies, as well as associated characteristics Methods: This retrospective cohort study analyzed pre-3V and post-3V data on 493 patients diagnosed with hematologic malignancies across a large Midwestern health system between August 28, 2021, and November 1, 2021. For antibody testing, S1 spike antigen of the SARS-CoV-2 virus titer was used to determine serostatus. Results: Among 493 participants, 274 (55.6%) were seropositive both pre- and post-3V (+/+) while 115 (23.3%) seroconverted to positive from prior negative following the third dose (-/+). The remaining 104 (21.1%) were seronegative both before and after 3V (-/-). No participant was seropositive pre-3V and seronegative post-3V (+/-). Results showed a statistically significant increase in the proportion of seropositivity after receiving a third COVID

    Source: institutionalrepository.aah.org
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of mtmdphd
      mtmdphd

      Real World Third COVID19 Vaccine Dosing and Antibody Response in Patients with Hematologic Malignancies [Jul 18, 2022] @mtmdphd , Hallmeyer, @vrepublic , Liao, @mullane_michael @scmedlin , Copeland, @JimW9200 @JPCRR https://t.co/CnXLOfmBVw #COVID19nCancer #COVID19Vaccine #IDonc https://t.co/IcDJIQMz5E

  • Mashup Score: 1
    Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19 - 8 month(s) ago

    Patients treated recently for a B-lymphoid malignancy are shown to have particularly high risks of severe COVID-19 compared to multiple control cohorts of patients with cancer and COVID-19.

    Source: aacrjournals.org
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of mtmdphd
      mtmdphd

      Patients recently treated for B-lymphoid malignancies show increased risk of severe COVID-19: a #CCC19 registry analysis [Mar 9, 2022] @rubinstein_md et al. @mtmdphd @COVID19nCCC @BCD_AACR https://t.co/IMEbvgZI4Q #COVID19nCancer #COVID19 #bmtsm #leusm #lymsm #mmsm #mpnsm https://t.co/D0xwL8cfqB

  • Mashup Score: 0
    COVID-19 and Cancer—A Review of the Registry-Based Pandemic Response - 9 month(s) ago

    This review describes the registry efforts made during the COVID-19 pandemic with the aim of investigating and sharing information about the history, risk factors, and outcomes of patients with COVID-19 and cancer.

    Source: jamanetwork.com
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of mtmdphd
      mtmdphd

      COVID-19 and cancer: A review of the registry-based pandemic response [Sep 2, 2021] @ADesaiMD @DrTJM_MD et al. @JAMAOnc https://t.co/98nOR8ovCS #COVID19nCancer #CCC19 @COVID19nCCC

Load More